Philip A Cole Selected Research

Histone Acetyltransferases (Histone Acetyltransferase)

1/2021	Discovery of spirohydantoins as selective, orally bioavailable inhibitors of p300/CBP histone acetyltransferases.
1/2019	MITF Expression Predicts Therapeutic Vulnerability to p300 Inhibition in Human Melanoma.
1/2019	Combination Targeting of the Bromodomain and Acetyltransferase Active Site of p300/CBP.
10/2017	Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours.
12/2016	Modulation of p300/CBP Acetylation of Nucleosomes by Bromodomain Ligand I-CBP112.
9/2011	Inhibition of the acetyltransferases p300 and CBP reveals a targetable function for p300 in the survival and invasion pathways of prostate cancer cell lines.
7/2008	Fungal Rtt109 histone acetyltransferase is an unexpected structural homolog of metazoan p300/CBP.
6/2004	Bisubstrate analogue structure-activity relationships for p300 histone acetyltransferase inhibitors.
11/2002	Down-regulation of p300/CBP histone acetyltransferase activates a senescence checkpoint in human melanocytes.
10/2002	Structure of the GCN5 histone acetyltransferase bound to a bisubstrate inhibitor.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Philip A Cole Research Topics

Disease

41	Neoplasms (Cancer) 10/2022 - 10/2002
4	Prostatic Neoplasms (Prostate Cancer) 01/2019 - 09/2011
4	Melanoma (Melanoma, Malignant) 01/2019 - 11/2002
3	Carcinoma (Carcinomatosis) 11/2021 - 09/2010
3	Leukemia 12/2016 - 07/2005
3	Hepatocellular Carcinoma (Hepatoma) 07/2012 - 09/2005
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2020 - 01/2019
2	Carcinogenesis 01/2019 - 09/2010
2	Pneumonia (Pneumonitis) 03/2014 - 10/2011
2	Weight Gain 04/2013 - 12/2010
2	Inflammation (Inflammations) 10/2011 - 05/2010
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 08/2011 - 09/2005
2	Genetic Translocation (Chromosomal Translocation) 08/2011 - 09/2010
2	Genomic Instability 02/2011 - 07/2008
2	T-Cell Leukemia (Leukemia, T Cell) 05/2003 - 07/2002
1	Reperfusion Injury 01/2021
1	Colorectal Neoplasms (Colorectal Cancer) 01/2020
1	Neoplasm Metastasis (Metastasis) 01/2019
1	Immune System Diseases (Immune Disorders) 05/2017
1	Obesity 01/2017
1	Endotoxemia 01/2017
1	Insulin Resistance 01/2017
1	Hyperglycemia 01/2017
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 10/2015
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 11/2011
1	Fibrosis (Cirrhosis) 10/2011
1	Metabolic Diseases (Metabolic Disease) 12/2010
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 12/2010
1	Tauopathies 09/2010

Drug/Important Bio-Agent (IBA)

12	Proteins (Proteins, Gene)FDA Link 10/2022 - 10/2002
12	Histones (Histone)IBA 10/2022 - 07/2002
10	Histone Acetyltransferases (Histone Acetyltransferase)IBA 01/2021 - 10/2002
7	EnzymesIBA 10/2022 - 06/2004
5	Pharmaceutical PreparationsIBA 10/2022 - 06/2004
5	LipidsIBA 01/2022 - 01/2016
4	Histone Deacetylases (Histone Deacetylase)IBA 10/2022 - 07/2005
4	Histone Deacetylase InhibitorsIBA 11/2021 - 06/2014
4	Phosphoric Monoester Hydrolases (Phosphatases)IBA 10/2021 - 01/2016
4	Lysine (L-Lysine)FDA Link 01/2020 - 10/2002
4	Phosphotransferases (Kinase)IBA 01/2020 - 11/2011
3	Protein Kinases (Protein Kinase)IBA 01/2022 - 01/2018
3	AcetyltransferasesIBA 10/2021 - 09/2011
3	ChromatinIBA 01/2020 - 07/2002
3	Transcription Factors (Transcription Factor)IBA 05/2017 - 10/2002
3	GhrelinIBA 10/2015 - 12/2010
3	ErbB Receptors (EGF Receptor)IBA 11/2011 - 06/2006
2	Biological ProductsIBA 01/2022 - 11/2002
2	PTEN Phosphohydrolase (PTEN Phosphatase)IBA 01/2022 - 01/2021
2	Phospholipids (Phosphatides)FDA LinkGeneric 10/2021 - 01/2020
2	Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA 01/2021 - 01/2018
2	p300-CBP-associated factorIBA 01/2019 - 01/2017
2	I-CBP112IBA 01/2019 - 12/2016
2	UbiquitinIBA 01/2018 - 05/2017
2	Androgen Receptors (Androgen Receptor)IBA 10/2017 - 09/2011
2	AndrogensIBA 10/2017 - 09/2011
2	LipopolysaccharidesIBA 01/2017 - 05/2010
2	Peptide Hormones (Polypeptide Hormones)IBA 10/2015 - 12/2010
2	DNA (Deoxyribonucleic Acid)IBA 10/2013 - 07/2005
2	GO-CoA-TatIBA 04/2013 - 12/2010
2	Peptides (Polypeptides)IBA 10/2011 - 03/2004
2	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 06/2006 - 05/2006
2	Trans-Activators (Trans-Acting Factor)IBA 03/2004 - 05/2003
1	PanobinostatIBA 11/2021
1	TensinsIBA 10/2021
1	Protein Isoforms (Isoforms)IBA 01/2021
1	Oncogene Proteins (Oncogene Protein)IBA 01/2020
1	NEO2734IBA 01/2020
1	entinostat (MS 275)IBA 01/2019
1	Microphthalmia-Associated Transcription FactorIBA 01/2019
1	CREB-Binding ProteinIBA 10/2017
1	Ligases (Synthetase)IBA 05/2017
1	Insulin (Novolin)FDA Link 01/2017
1	LigandsIBA 12/2016
1	phosphatidylinositol 3,4,5-triphosphateIBA 07/2016
1	Phosphatidylinositols (Phosphatidylinositol)IBA 01/2016
1	Membrane Proteins (Integral Membrane Proteins)IBA 10/2015
1	AcyltransferasesIBA 10/2015
1	MethyltransferasesIBA 12/2014
1	Histone DemethylasesIBA 09/2014
1	Fc Receptors (Fc Receptor)IBA 03/2014
1	Cisplatin (Platino)FDA LinkGeneric 10/2013
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 09/2013
1	MicroRNAs (MicroRNA)IBA 07/2012
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 11/2011
1	Adenosine (Adenocard)FDA LinkGeneric 10/2011
1	Hyaluronic Acid (Hyaluronan)IBA 10/2011
1	Adenosine A2A Receptor (Adenosine A2A Receptors)IBA 10/2011
1	Small Interfering RNA (siRNA)IBA 09/2011
1	Histone ChaperonesIBA 02/2011
1	Nucleosomes (Nucleosome)IBA 02/2011
1	Glucose (Dextrose)FDA LinkGeneric 12/2010
1	AntibodiesIBA 09/2010
1	Nuclear Proteins (Protein, Nuclear)IBA 09/2010
1	sulforaphaneIBA 05/2010
1	isothiocyanic acidIBA 05/2010
1	CarcinogensIBA 05/2010

Therapy/Procedure

6	Therapeutics 09/2011 - 06/2002
2	Castration 10/2017 - 09/2011
1	Drug Therapy (Chemotherapy) 01/2020
1	Immunotherapy 09/2013